A major hurdle to the efficacy of adoptive cell therapy and chimeric antigen receptors T-cell therapy is the choice of antigen(s) to target. An article in this issue addresses this by capitalizing on the synergistic effect of pathogen-based immunotherapy and adoptive cell therapy that results in epitope/antigen spreading and enhancement of the endogenous T-cell response against antigens not originally targeted.See article by Xin et al., p. 7.

中文翻译：

---

肿瘤抗原异质性：用于实体瘤的过继T细胞疗法的“房间里的大象”。

过继细胞疗法和嵌合抗原受体T细胞疗法的功效的主要障碍是靶标抗原的选择。本期的一篇文章通过利用基于病原体的免疫疗法和过继性细胞疗法的协同作用来解决此问题，这种协同作用导致表位/抗原扩散并增强了针对最初未被靶向的抗原的内源性T细胞反应。 。，p。7。